By Iain Gilbert
Date: Tuesday 22 Apr 2025
(Sharecast News) - Drugmaker AstraZeneca said on Tuesday that it had received "positive high-level results" from a Phase III trial on its Enhertu candidate, developed in conjunction with Daiichi Sankyo.
London close: Stocks fall as China retaliates to... | 09-Apr-2025 | ShareCast |
AstraZeneca's Enhertu gets further EU approval | 04-Apr-2025 | ShareCast |
London close: Stocks slide in global reaction to... | 03-Apr-2025 | ShareCast |
UK pharma stocks avoid selloff | 03-Apr-2025 | ShareCast |
AstraZeneca makes regulatory progress with Imfin... | 31-Mar-2025 | ShareCast |
Enhertu combination improved PFS in 1L HER2+ mBC | 22-Apr-2025 | 07:00 | RNS |
Result of AGM | 11-Apr-2025 | 17:30 | RNS |
Imfinzi approved in EU for AEGEAN | 04-Apr-2025 | 07:05 | RNS |
Enhertu approved in EU in post-ET breast cancer | 04-Apr-2025 | 07:00 | RNS |
Total Voting Rights | 01-Apr-2025 | 15:00 | RNS |
Questor :AstraZeneca | 29-Apr-2014 | Telegraph |
Questor : AstraZeneca | 24-Jan-2014 | Telegraph |
Questor:AstraZeneca | 22-Dec-2011 | Telegraph |
Investment Column:AstraZeneca | 28-Oct-2011 | The Independent |
Investment Column: AstraZeneca | 23-Jun-2011 | The Independent |
Currency | UK Pounds |
Share Price | 10,400.00p |
Change Today | -44.00p |
% Change | -0.42 % |
52 Week High | 13,276.00 |
52 Week Low | 9,667.00 |
Volume | 2,797,657 |
Shares Issued | 1,550.62m |
Market Cap | £161,265m |
RiskGrade | 123 |
Value |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Price Trend |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Income |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Growth |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Strong Buy | 10 |
Buy | 14 |
Neutral | 4 |
Sell | 0 |
Strong Sell | 1 |
Total | 29 |
Latest | Previous | |
---|---|---|
2nd Interim | 1st Interim | |
Ex-Div | 20-Feb-25 | 08-Aug-24 |
Paid | 24-Mar-25 | 09-Sep-24 |
Amount | 210.00¢ | 100.00¢ |
Time | Volume / Share Price |
17:31 | 99 @ 10,472.38p |
17:31 | 335 @ 10,472.03p |
17:31 | 100 @ 10,471.82p |
17:31 | 139 @ 10,471.88p |
11:12 | 800,000 @ 10,470.00p |
You are here: research